Baricitinib provides greater improvements in patient-reported outcomes across all disease activity levels compared to placebo and adalimumab in rheumatoid arthritis - Taylor, P; Blanco, R; Ikeda, K; Jia, B; Chen, YF; Walls, C; Haladyj, E; Fautrel, B (BMJ Publishing Group, 2021)